Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
Contains abacavir

Is Ziagen affected by genetics?

Yes, but not in a way Gene2Rx can test. People who carry HLA-B*57:01 have a high risk of a serious hypersensitivity reaction to abacavir, and the label requires screening before starting. Gene2Rx does not test HLA genes, so this result has to come from a clinical lab.

Used for: HIV infection (as part of combination antiretroviral therapy)

Ziagen (abacavir) requires an HLA-B*57:01 test before you start it, and Gene2Rx does not test HLA genes, so that result has to come from a clinical lab. Before screening, about 5 to 8 percent of people starting abacavir for HIV had a hypersensitivity reaction, usually in the first 6 weeks, and reactions can be fatal, especially on re-exposure. In 2008 the PREDICT-1 trial showed that screening for HLA-B*57:01 before treatment and not giving abacavir to carriers prevented immunologically confirmed reactions, and the FDA label was updated to recommend screening. The label now says to test everyone before starting or restarting abacavir unless an earlier result is documented, and abacavir is contraindicated in people who carry HLA-B*57:01. This applies to every abacavir-containing product, including Epzicom, Trizivir and Triumeq.

What's in Ziagen

Abacavir No known pharmacogenetics

No strong published pharmacogenetic guideline currently applies to abacavir.

Abacavir is a nucleoside reverse transcriptase inhibitor. It is cleared mainly by alcohol dehydrogenase and glucuronidation, not by the cytochrome P450 enzymes behind most drug-gene results, and HLA-B status does not change abacavir levels or how well it works. The HLA-B*57:01 link is immune: abacavir binds to the HLA-B*57:01 molecule and changes which of the body's own protein fragments it displays, so T cells react to them. Typical symptoms are two or more of fever, rash, nausea, vomiting or abdominal pain, tiredness, cough and shortness of breath, worsening if the drug is continued. Screening greatly lowers the risk but does not remove it: in the label's pooled trials the reaction rate fell from 8 percent to about 1 percent when carriers were excluded. Abacavir must be stopped at once if a reaction is suspected, whatever the test result.

What this means for you

If you've been prescribed an abacavir-containing HIV regimen, your HLA-B*57:01 result should already be on file before you start; keep a copy, because the label allows a documented earlier result to stand in for repeat testing. Gene2Rx does not test HLA-B*57:01, from consumer DNA data or whole-genome sequencing, so a Gene2Rx report contains no abacavir result, and nothing else in it can be read as clearing you for abacavir. The test comes from a clinical lab, ordered by your HIV clinician. If you have ever had a reaction to abacavir, never take it again, even briefly: restarting after a reaction can cause a rapid, life-threatening reaction. Don't stop or change HIV medicines on your own; talk to your clinician.

FAQ

Do all HIV patients get HLA-B*57:01 tested?

Everyone who may be prescribed abacavir should be. The FDA label says to test before starting or restarting it unless a previous result is documented, and CPIC recommends testing everyone who has not taken abacavir before. People on regimens without abacavir do not need the result for their current treatment.

Can a prior abacavir reaction be re-tested?

No. After a suspected abacavir hypersensitivity reaction, the label says never to restart abacavir, whatever any HLA-B*57:01 test shows. The test is for judging risk before the first dose, not for clearing someone who has already reacted.

How common is HLA-B*57:01 across populations?

It varies by ancestry. CPIC puts the allele frequency at about 6 to 7 percent in European populations, with up to 20 percent of people carrying it in some Southwest Asian populations. It is less common in African and East Asian populations and almost absent in some, including Japanese. Because ancestry is a poor guide for one person, the label and CPIC call for testing everyone before abacavir rather than testing by ancestry.

Find out how your genetics affect Ziagen

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.